Lite Strategy (LITS) Operating Expenses (2010 - 2026)
Lite Strategy (LITS) posted quarterly Operating Expenses of $21.6 million for Q1 2026, up 679.02% year-over-year from $2.8 million in Q1 2025, and down 27.65% quarter-over-quarter from $29.9 million in Q4 2025.
Lite Strategy (LITS) Operating Expenses (2010 - 2026) Analysis & Trends
Lite Strategy's Operating Expenses history runs 17 years deep, the most recent figure standing at $21.6 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 679.02% year-over-year to $21.6 million; the TTM figure through Mar 2026 stood at $58.1 million (up 73.12% YoY), while the FY2025 annual figure was $17.5 million, down 65.61% from the prior year.
- Operating Expenses for Q1 2026 stood at $21.6 million, down from $29.9 million in the prior quarter.
- The five-year high for Operating Expenses was $31.3 million in Q1 2022, with the low at $2.8 million in Q1 2025.
- The 5-year median for Operating Expenses is $12.5 million (2023), against an average of $15.8 million.
- Peak annual rise in Operating Expenses reached 765.46% in 2025, while the deepest fall reached 84.84% in 2025.
- Lite Strategy's Operating Expenses stood at $23.8 million in 2022, then tumbled by 49.89% to $11.9 million in 2023, then plunged by 71.07% to $3.5 million in 2024, then soared by 765.46% to $29.9 million in 2025, then retreated by 27.65% to $21.6 million in 2026.
- Business Quant data shows LITS's Operating Expenses at $21.6 million in Q1 2026, $29.9 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 541.02 Mn |
| 10 | Lite Strategy | 36.07 Mn | 28.52 Mn | - | 21.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.61 Mn |
| Dec 31, 2025 | 29.87 Mn |
| Sep 30, 2025 | 3.74 Mn |
| Jun 30, 2025 | 2.88 Mn |
| Mar 31, 2025 | 2.77 Mn |
| Dec 31, 2024 | 3.45 Mn |
| Sep 30, 2024 | 8.35 Mn |
| Jun 30, 2024 | 18.98 Mn |
| Mar 31, 2024 | 9.83 Mn |
| Dec 31, 2023 | 11.93 Mn |
| Sep 30, 2023 | 10.02 Mn |
| Jun 30, 2023 | 12.54 Mn |
| Mar 31, 2023 | 22.29 Mn |
| Dec 31, 2022 | 23.81 Mn |
| Sep 30, 2022 | 26.95 Mn |
| Jun 30, 2022 | 27.61 Mn |
| Mar 31, 2022 | 31.25 Mn |
| Dec 31, 2021 | 29.46 Mn |
| Sep 30, 2021 | 27.86 Mn |
| Jun 30, 2021 | 22.93 Mn |